GLP-1 and Fertility: What to Know Before Starting Semaglutide or Tirzepatide

Every week, physicians who prescribe GLP-1 medications field some version of the same question: "I want to get pregnant at some point. Is this safe? When should I stop?"

It's a completely legitimate question — and the honest answer is more nuanced than most online resources suggest. The research on GLP-1 medications specifically during pregnancy is limited, the recommendations are evolving, and the fertility picture is actually more interesting than most people realize.

Here's what we actually know.

Do GLP-1 Medications Affect Fertility?

This is where things get counterintuitive. For many women, GLP-1 medications may *improve* fertility — not impair it. The mechanism makes sense when you think about it:

The weight-fertility connection: Obesity is a significant driver of hormonal disruption in women. Elevated body fat increases estrogen production (through aromatase activity in adipose tissue), disrupts LH pulsatility, and worsens insulin resistance — all of which can impair ovulation. Losing even 5-10% of body weight often restores ovulatory cycles in women with obesity-related anovulation.

PCOS specifically: Polycystic ovary syndrome is one of the most common causes of infertility in women of reproductive age. Insulin resistance is central to PCOS pathophysiology, and GLP-1 medications address insulin resistance directly. Multiple studies show GLP-1 agonists improve hormonal profiles in women with PCOS — lower androgens, more regular cycles, improved ovulation rates.

The practical implication: Women who weren't ovulating regularly because of weight or PCOS may start ovulating when they begin GLP-1 therapy. This is relevant for contraception (don't assume you can't get pregnant just because you weren't before), and it's relevant for fertility planning (weight loss as a path to natural conception is real and documented).

What Happens If You Get Pregnant While on a GLP-1?

This scenario happens more often than you'd think — both because GLP-1 medications improve ovulation in women who weren't cycling, and because the medications are increasingly prescribed across the entire reproductive age spectrum.

The current guidance from major medical organizations (FDA, ACOG, Endocrine Society) is consistent: GLP-1 receptor agonists should not be used during pregnancy.

The reasons:

Animal data is concerning: Rodent studies with semaglutide and liraglutide showed embryofetal toxicity, reduced fetal growth, and skeletal abnormalities — though at doses higher than typical human doses. These findings don't automatically translate to humans, but they're enough to warrant caution.

Human data is limited: There simply aren't enough human studies to establish safety during pregnancy. The medications are new enough that long-term data on in-utero exposure doesn't exist. The absence of evidence isn't evidence of safety.

The mechanism raises questions: GLP-1 receptors are expressed in fetal tissue. What role GLP-1 signaling plays in fetal development isn't fully understood.

The weight loss itself is relevant: Rapid weight loss during early pregnancy, which GLP-1 medications can cause, may not be appropriate even when the medications are stopped — nutritional adequacy during the first trimester matters.

If you discover you're pregnant while on a GLP-1 medication, the standard recommendation is to stop the medication and contact your physician immediately. Many pregnancies in women who've been on GLP-1s proceed normally — the animal data involves doses and exposures different from human therapeutic use — but physician guidance is essential.

How Long Before Trying to Conceive Should You Stop?

This is the practical question, and it depends on which medication you're taking.

Semaglutide (Ozempic/Wegovy): Half-life of approximately 7 days. Meaningful systemic clearance takes about 5 weeks (5 half-lives). Most guidelines recommend stopping at least 2 months before attempting to conceive. Some physicians recommend 3 months to be conservative.

Tirzepatide (Mounjaro/Zepbound): Half-life of approximately 5 days. Similar clearance window. The 2-month recommendation applies here as well.

Liraglutide (Saxenda/Victoza): Half-life of approximately 13 hours — much shorter. Clearance is faster, and 1-2 months is typically sufficient.

These timelines exist not just for medication clearance but to allow physiologic stabilization. Weight cycling — losing rapidly, then stopping the medication, then regaining — isn't ideal around conception. The goal is to reach a stable weight before becoming pregnant.

What About Breastfeeding?

Even less data exists here than for pregnancy. GLP-1 medications are detectable in rodent breast milk, and the possibility of infant exposure via breastfeeding cannot be excluded. The current guidance is to avoid GLP-1 medications while breastfeeding until more data is available.

The PCOS Situation: A Closer Look

Women with PCOS deserve special mention because they're a significant portion of GLP-1 users and the fertility picture is complex.

GLP-1 medications genuinely help PCOS. Studies show: - Reduced fasting insulin and HOMA-IR (insulin resistance marker) - Lower free androgen levels (less testosterone, less SHBG suppression) - More regular menstrual cycles - Improved ovulation rates in some studies - Weight loss, which further improves all of the above

For PCOS women not currently trying to conceive, GLP-1 therapy can be a valuable tool that moves them toward better hormonal health. The irony: the medication may be making them more fertile even as it can't be used during pregnancy.

If you have PCOS, are on GLP-1 therapy, and are sexually active — take contraception seriously. The assumption that irregular cycles equals infertility is responsible for a lot of unplanned pregnancies when GLP-1 therapy normalizes ovulation.

The Practical Decision Framework

If you're not planning to conceive in the next 6 months: GLP-1 therapy can proceed normally. Use reliable contraception. Many women spend this window making meaningful progress on their metabolic health, which improves their baseline before pregnancy.

If you're planning to conceive in 3-6 months: Discuss timing with your physician. The goal is to reach a stable weight before stopping, then allow the clearance window before attempting conception. Starting to decelerate dose escalation earlier than planned may make the transition smoother.

If you're actively trying to conceive: Stop GLP-1 therapy at least 2 months before (for semaglutide or tirzepatide). Focus on weight stability through diet and exercise. If PCOS is a factor, discuss alternative medical support for ovulation induction with your physician.

If you're undergoing IVF or fertility treatments: Most fertility clinics recommend stopping GLP-1 medications before egg retrieval. The medication's effects on ovarian stimulation response and embryo quality aren't well studied. Defer to your reproductive endocrinologist's recommendations.

If you get pregnant unexpectedly while on GLP-1: Stop the medication. Contact your OB. Don't panic — the risk data in humans is limited and many exposures haven't resulted in adverse outcomes — but this is a decision that needs physician oversight.

Weight Regain After Stopping GLP-1

One concern that's realistic to address: stopping GLP-1 therapy often leads to some weight regain, especially if the medication was doing heavy lifting for appetite control. This is physiologically normal — the drug's appetite-suppressing effect dissipates.

For women who've used GLP-1 to lose meaningful weight before pregnancy, the goal before stopping is to have built habits (diet patterns, activity) that can maintain a reasonable portion of the progress without pharmacologic support. Not a perfect outcome, but weight loss achieved before pregnancy has independent metabolic benefits that don't fully disappear with some regain.

What to Ask Your Doctor

If you're on a GLP-1 medication and thinking about pregnancy:

1. What's my target weight before we'd discuss stopping?
2. How long before trying to conceive should I stop the medication?
3. What's your recommendation on contraception in the meantime?
4. If I have PCOS, what monitoring or support would you recommend after stopping?
5. What does managing my weight look like during pregnancy and postpartum?

These are standard questions that a physician prescribing GLP-1 to a woman of reproductive age should be prepared to address. If the conversation feels rushed or incomplete, that's worth noting.

At Marrow, we include this discussion as a standard part of the intake process for women who are premenopausal. The goal is a plan that serves both your current metabolic health and your future plans — not a one-size-fits-all prescription without that context.